About CRI

Jeffrey V. Ravetch, M.D., Ph.D.

The Rockefeller University
New York, NY

Dr. Ravetch is currently the Theresa and Eugene Lang Professor at The Rockefeller University and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology. He earned his doctorate at The Rockefeller University – Cornell Medical School M.D./Ph.D. program in genetics and his doctor of medicine from Cornell University Medical School. His postdoctoral studies were at the National Institutes of Health, where he identified and characterized the genes for the human immunoglobulin M (IgM) antibody and the DNA elements involved in switch recombination. As a faculty member of Memorial Sloan-Kettering Cancer Center and Cornell Medical College, Dr. Ravetch and colleagues in his laboratory cloned the first genes for Fc receptors, identified the SHIP inhibitory receptor signaling pathway, and contributed significantly to understanding the mechanisms of antibody-mediated effector responses, establishing the FcR pathways as fundamental components of the immune response.

In addition to his studies on antibody receptors, Dr. Ravetch has made fundamental contributions to the genetics of the malaria parasite and, with the identification of the first cytokine, IP-10, established this class of molecules as novel mediators of inflammation. He has served as a member of the Scientific Advisory Boards of the Cancer Research Institute, the Irvington Institute for Immunological Research, and the Damon Runyon Foundation. He has also served as a member of the Scientific Advisory Boards of Millennium Pharmaceuticals, Exelexis Pharmaceuticals, Regeneron Pharmaceuticals, Medimmune, Genentech, and Novartis.  He founded MacroGenics in 2000 with Leroy Hood, Alan Aderem, and Reudi Aebersold and Virdante Pharmaceuticals in 2007. Also in 2007, Dr. Ravetch received CRI's William B. Coley Award for Distinguished Research in Basic and Tumor Immunology.